Barrett's esophagus medical therapy: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {{Barrett's esophagus}} {{CMG}} ==Overview== ==Medical Therapy== Treatment may be important even if you do not feel any symptoms. ===Lifestyle changes include:=...")
 
No edit summary
 
(20 intermediate revisions by 5 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Barrett's esophagus}}
{{Barrett's esophagus}}
 
{{CMG}}; {{AE}} {{MKK}} {{AMK}}
{{CMG}}


==Overview==
==Overview==
According to the American College of Gastroenterology, the [[patients]] with [[Barrett's esophagus]] are treated with both lifestyle changes and [[medications]]. The lifestyle changes includes avoiding [[dietary]] [[fat]], [[chocolate]], [[caffeine]], [[peppermint]], [[alcohol]], [[tobacco]], avoiding lying down after meals, losing [[weight]], sleeping with the [[head]] of the bed elevated and taking all [[medications]] with plenty of [[water]]. The [[medications]] used to treat [[Barrett's esophagus]] are [[H₂-receptor antagonist|H2-receptor antagonists,]] [[Proton pump inhibitor]] and photosensitizers.


==Medical Therapy==
==Medical Therapy==
 
According to the American College of Gastroenterology, indication for the medical therapy in [[Barrett's esophagus]] [[patients]] are:<ref name="urlDiagnosis and Management of Barrett’s Esophagus | American College of Gastroenterology">{{cite web |url=https://gi.org/guideline/diagnosis-and-management-of-barretts-esophagus/ |title=Diagnosis and Management of Barrett’s Esophagus &#124; American College of Gastroenterology |format= |work= |accessdate=}}</ref><ref name="pmid22798736">{{cite journal |vauthors=Amano Y, Kinoshita Y |title=Barrett esophagus: perspectives on its diagnosis and management in asian populations |journal=Gastroenterol Hepatol (N Y) |volume=4 |issue=1 |pages=45–53 |year=2008 |pmid=22798736 |pmc=3394474 |doi= |url=}}</ref>
Treatment may be important even if you do not feel any symptoms.
*Patients with BE should receive once-daily [[PPI]] therapy. Routine use of twice-daily dosing is not recommended unless necessitated because of poor control of [[reflux]] [[symptoms]] or [[esophagitis]].
 
*[[Aspirin]] or [[nonsteroidal anti-inflammatory drugs]] should not be routinely prescribed to patients with BE as an antineoplastic strategy. Similarly, other putative chemopreventive agents currently lack sufficient [[evidence]] and should not be administered routinely.
===Lifestyle changes include:===
===Lifestyle changes include:===
* Avoiding dietary fat, chocolate, caffeine, and peppermint because they may cause lower esophageal pressure and allow [[stomach acid]] to flow backwards
* Avoiding [[dietary]] [[fat]], [[chocolate]], [[caffeine]], and [[peppermint]] because they may cause lower [[esophageal]] [[pressure]] and allow [[stomach acid]] to [[flow]] backwards
* Avoiding alcohol and tobacco
* Avoiding [[alcohol]] and [[tobacco]]
* Avoiding lying down after meals
* Avoiding lying down after meals
* Losing weight
* Losing [[weight]]
* Sleeping with the head of the bed elevated
* Sleeping with the [[head]] of the bed elevated
* Taking all medications with plenty of water
* Taking all [[medications]] with plenty of [[water]]


===Medications to relieve symptoms and control gastroesophageal reflux include:===
===Medications to relieve symptoms and control gastroesophageal reflux include:===
* [[Antacids]] after meals and at bedtime
*[[H₂-receptor antagonist|H2-receptor antagonists]]:
* [[Cholinergic agents]]
**These are competitive blockers of [[histamine]] at [[H2]] [[receptor]] blockers, it inhibits [[acid]] [[secretion]] from [[gastric]] [[parietal cells]]. [[Drugs]] in this categories are:
* [[Histamine H2 receptor blockers]]
***[[Ranitidine]]
* [[Promotility agents]]
***[[Famotidine]]
* [[Proton pump inhibitors]]:  Proton pump inhibitor drugs have not yet been proven to prevent esophageal cancer.  
***[[Nizatidine]]
***[[Cimetidine]]  
*[[Proton pump inhibitor]]:
**These acts by inhibiting of the [[H+/K+ ATP-ase|H+/K+ adenosine triphosphatase (ATPase)]] [[enzyme]] [[system]] which further inhibits [[gastric acid]] [[secretions]] by [[gastric]] [[parietal cells]]. Various types of [[proton pump inhibitors]] are:
***[[Omeprazole]]
***[[Lansoprazole]]
***[[Esomeprazole]]
***[[Dexlansoprazole]]
***[[Rabeprazole]]
***[[Pantoprazole]]
*[[Photosensitizer|Photosensitizers]]
**Porfimer is a [[photosensitizer]] is used along with photodynamic [[therapy]].
**It acts by absorbing light and transforms into short-lived singlet state, further transformed to a reactive triplet state.
**During the [[triplet]] [[state]], it produces free radical which react with cell membranes and causes damage to the [[mitochondria]], [[endoplasmic reticulum]], and/or plasma membranes.
* [[Antacids]] after meals and at [[bedtime]]


==References==
==References==
Line 30: Line 44:
{{WH}}
{{WH}}
{{WS}}
{{WS}}
[[Category: (name of the system)]]

Latest revision as of 19:03, 21 February 2018

Barrett's Esophagus Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Barrett's Esophagus from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Endoscopic Therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Barrett's esophagus medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Barrett's esophagus medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Barrett's esophagus medical therapy

CDC on Barrett's esophagus medical therapy

Barrett's esophagus medical therapy in the news

Blogs on Barrett's esophagus medical therapy

Directions to Hospitals TreatingBarrett's esophagus

Risk calculators and risk factors for Barrett's esophagus medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Manpreet Kaur, MD [2] Amresh Kumar MD [3]

Overview

According to the American College of Gastroenterology, the patients with Barrett's esophagus are treated with both lifestyle changes and medications. The lifestyle changes includes avoiding dietary fat, chocolate, caffeine, peppermint, alcohol, tobacco, avoiding lying down after meals, losing weight, sleeping with the head of the bed elevated and taking all medications with plenty of water. The medications used to treat Barrett's esophagus are H2-receptor antagonists, Proton pump inhibitor and photosensitizers.

Medical Therapy

According to the American College of Gastroenterology, indication for the medical therapy in Barrett's esophagus patients are:[1][2]

  • Patients with BE should receive once-daily PPI therapy. Routine use of twice-daily dosing is not recommended unless necessitated because of poor control of reflux symptoms or esophagitis.
  • Aspirin or nonsteroidal anti-inflammatory drugs should not be routinely prescribed to patients with BE as an antineoplastic strategy. Similarly, other putative chemopreventive agents currently lack sufficient evidence and should not be administered routinely.

Lifestyle changes include:

Medications to relieve symptoms and control gastroesophageal reflux include:

References

  1. "Diagnosis and Management of Barrett's Esophagus | American College of Gastroenterology".
  2. Amano Y, Kinoshita Y (2008). "Barrett esophagus: perspectives on its diagnosis and management in asian populations". Gastroenterol Hepatol (N Y). 4 (1): 45–53. PMC 3394474. PMID 22798736.

Template:WH Template:WS